Dow Jones Newswires: Reckitt Benckiser cuts 2019 guidance after weak performance

This post was originally published on this site

Reckitt Benckiser Group PLC on Tuesday cut its guidance for the second time this year after a weak performance from its health business, which was hurt by the U.S., China issues.

The consumer-goods company RB, -2.21%  , which houses Dettol, Harpic and durex among its brands, said it expects revenue for the year to be flat to 2% growth. At the time of its half-year earnings in July, the company lowered its guidance to between 2% to 3% growth from the previously guided 3% to 4%.

Revenue for the third quarter ended Sept. 30 rose 5.3% to 3.29 billion pounds ($4.27 billon) taking the total for the year to date to GBP9.53 billion. This compares with GBP3.12 billion and GBP9.26 billion for the same periods last year. On a like-for-like basis third-quarter revenue was up 1.6% and 0.9% for the year to date.

Within this the health unit’s revenue for the quarter was GBP1.96 billion, a 0.3% fall on a like-for-like basis compared with the third quarter of last year. This unit contributes 61% of the overall net revenue.